Timothy Harrison - Concepedia

Author

Timothy Harrison

Also Known As

James Chalmers, Lennart Råhlen, T W Harrison, Timothy Harrison, Timothy W Harrison, Timothy W. Harrison, Timothy Ward Harrison

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

University of Nottingham MSD (UK) Limited (United Kingdom)Merck & Co., Inc., Rahway, NJ, USA (United States)Nottingham Biomedical Research Centre AstraZeneca (United States)

About

Timothy Harrison is an author at University of Nottingham specializing in medicine, biochemistry, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	1.8K
2	Natural Sciences	9	9	457
3	Engineering	6	6	192
4	Allergy	5	5	911
5	Allergy Medicine	3	3	631

Timothy Harrison

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial Phillip Monk, Richard Marsden, Victoria Tear, The Lancet Respiratory Medicine Sars-cov-2 InfectionCovid-19 PandemicImmunologyAntiviral TherapyRespiratory Infection	2020	448
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial William W. Busse, Eugene R. Bleecker, J Mark FitzGerald, The Lancet Respiratory Medicine AsthmaRheumatologyExtension TrialAllergyAllergy Medicine	2018	298
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial Tim Harrison, Pascal Chanez, Francesco Menzella, The Lancet Respiratory Medicine AsthmaSevere Eosinophilic AsthmaAllergyInflammatory Lung DiseaseAllergy Medicine	2020	168
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study Andrew Menzies‐Gow, Mark Gurnell, Liam G. Heaney, The Lancet Respiratory Medicine AsthmaAllergyPersonalised Reduction AlgorithmAllergy MedicineImmunology	2021	165
Inhaled Corticosteroids and the Risk of Pneumonia in People With Asthma Tricia M. McKeever, Timothy Harrison, Richard Hubbard, CHEST Journal AsthmaAllergyInflammatory Lung DiseaseRespiratory DiseasesRespiratory Infection	2013	150
Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations Tricia M. McKeever, Kevin Mortimer, Andrew Wilson, New England Journal of Medicine	2018	146
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial Richard Russell, Latifa Chachi, J. Mark FitzGerald, The Lancet Respiratory Medicine InflammationAsthmaPlacebo-controlled Phase 2Eosinophilic Airway InflammationAllergy	2018	130
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study David J. Jackson, Liam G. Heaney, Marc Humbert, The Lancet	2023	116
The Impact of Oral Corticosteroid Use on Bone Mineral Density and Vertebral Fracture Lesley J. Walsh, Sarah Lewis, Conroy Wong, American Journal of Respiratory and Critical Care Medicine	2002	114
Aryl sulfones: a new class of γ-secretase inhibitors Martin Teall, Paul Oakley, Timothy Harrison, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryBiochemistryMedicineNatural Sciences	2005	110

Page 1